Abstract
Matrix metalloproteinases (MMPs)are members of zinc-dependent endopeptidases implicated in a variety of physiological and pathological processes. Over the decades, MMPs have been studied for their role in cancer progression, migration, and metastasis. As a result, accumulated evidence of MMPs incriminating role has made them an attractive therapeutic target. Early generations of broad-spectrum MMP inhibitors exhibited potent inhibitory activities, which subsequently led to clinical trials. Unexpectedly, these trials failed to meet the desired goals, mainly due to the lack of efficacy, poor oral bioavailability, and toxicity. In this review, we discuss the regulatory role of MMPs in cancer progression, current strategies in targeting MMPs for cancer treatment including prodrug design and tumor imaging, and therapeutic value of MMPs as biomarkers in breast, lung, and prostate cancers.
| Original language | English |
|---|---|
| Pages (from-to) | 100-115 |
| Number of pages | 16 |
| Journal | Seminars in Cancer Biology |
| Volume | 56 |
| DOIs | |
| State | Published - Nov 20 2017 |
Bibliographical note
Copyright © 2017 Elsevier Ltd. All rights reserved.ASJC Scopus Subject Areas
- Cancer Research
Keywords
- Biomarker
- Cancer
- Matrix metalloproteinase
- Matrix metalloproteinase inhibitors
- Disease Susceptibility
- Humans
- Matrix Metalloproteinase Inhibitors/pharmacology
- Gene Expression Regulation, Neoplastic/drug effects
- Structure-Activity Relationship
- Molecular Targeted Therapy
- Signal Transduction/drug effects
- Disease Progression
- Matrix Metalloproteinases/chemistry
- Animals
- Neoplasms/diagnosis
- Biomarkers
- Disease Management
Disciplines
- Cancer Biology